India has taken a big step to fight against deadly disease like malaria. The Indian Council of Medical Research (ICMR) has created a new malaria vaccine in collaboration with the National Institute of Immune (DBT-NII), the National Institute of Immune (DBT-NII), the Department of Medical Research (ICMR) of India (RMRCB) and the National Institute of Malaria Research (NIMR). It is named Adfalcivax. This is the first such vaccine in India to target Plasmodium Phalsiparm, the most dangerous parasitic parasit of malaria at two different levels. Its specialty is that it will not only protect humans from malaria, but will also prevent its spread through mosquitoes.

What is Adfalcivax?

Adfalcivax is a special type of vaccine, which attacks two important stages of malaria parasites. In the first stage, when the parasitic spread infection in the human body and the second stage when this disease through mosquitoes reaches from one person to another. This means that this vaccine will not only save you from getting sick, but will also prevent malaria from spreading in the entire area. This vaccine has proved effective in the initial Tests conducted on animals. Scientists believe that it can be better in many cases with existing vaccines such as RTS, S/AS01 and R21/Matrix-M.

Vaccine made from this bacteria

In making this vaccine, safe bacteria called ‘Lactococcus lactis’ were used, which is already known in the vaccine development. In this, a strong vaccine has been made by combining effective elements against two different stages. This vaccine does not spoil up to 9 months at room temperature, which makes it very useful for areas where there is a lack of electricity or cold space. Also, it is made of cheap and safe substances, which is also economical.

Why is this vaccine special?

The biggest feature of Adfalcivax is that it kills malaria parasites on two fronts. Usually the rest of the vaccines target only one stage, but it works on both stages. This not only reduces the risk of malaria for a person, but also stops the spread of the disease through mosquitoes. Also, this vaccine also reduces the parasite’s attempt to dodge the body’s immunity and gives prolonged protection. It is made from cheap substances like alum, so that it can reach more and more people.

What is the plan ahead?

Adfalcivax is currently in the initial development stage. It will take time to reach the common people. According to ICMR, the plan of development and testing of vaccine is like this.

• GMP construction and toxicity testing: It will take about 2 years.
• Phase 1 clinical trial: For initial human testing, 2 more years are required.
• Phase 2B and Phase 3 Trial: 2.5 years for mass testing.
• Last approval and marketing license: This will require 6 more months.

In every phase, additional time of 6 months has also been kept, so that the work can be completed even if there is any delay. Overall, if everything goes well, then this vaccine can reach people in about 7 years.

Also read: Is there a knot in your breast? You can investigate themselves at home

Disclaimer: Some information given in the news is based on media reports. Before implementing any suggestion, you must consult the concerned expert.

Check out Below Health Tools-
Calculate your body mass index (BMI)

Calculate the age through age calculator